Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
Holding PTGX?
Track your performance easily

Protagonist Therapeutics (PTGX) Financial Statements

604 Followers

Protagonist Therapeutics Financial Overview

Protagonist Therapeutics's market cap is currently ―. The company's EPS TTM is $2.627; its P/E ratio is 17.10; Protagonist Therapeutics is scheduled to report earnings on November 6, 2024, and the estimated EPS forecast is $-0.60. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Dec 23Sep 23Jun 23
Income Statement-
Total Revenue$ 4.17M$ 254.95M$ 60.00M--
Gross Profit$ 4.17M$ 254.95M$ 60.00M--
EBIT$ -31.32M$ 206.31M$ 23.05M$ -34.10M$ -38.46M
EBITDA$ -28.81M$ 207.13M$ 23.88M$ -34.28M$ -38.60M
Net Income Common Stockholders$ -30.59M$ 207.34M$ 27.34M$ -34.10M$ -38.46M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 564.04M$ 322.67M$ 341.63M$ 320.73M$ 313.38M
Total Assets$ 614.63M$ 629.31M$ 357.95M$ 330.02M$ 320.45M
Total Debt$ 10.97M$ 462.00K$ 1.14M$ 1.80M$ 2.45M
Net Debt$ -553.07M$ -322.21M$ -340.49M$ -318.92M$ -310.94M
Total Liabilities$ 73.31M$ 68.83M$ 21.27M$ 27.87M$ 26.40M
Stockholders Equity$ 541.31M$ 560.41M$ 336.68M$ 302.15M$ 294.11M
Cash Flow-
Free Cash Flow$ 268.59M$ -27.67M$ 16.94M$ -27.02M$ -26.41M
Operating Cash Flow$ 268.62M$ -27.43M$ 16.96M$ -26.61M$ -26.24M
Investing Cash Flow$ -88.12M$ 6.07M$ -61.29M$ -13.56M$ 25.76M
Financing Cash Flow$ 2.57M$ 7.20M$ 527.00K$ 35.31M$ 108.17M
Currency in USD

Protagonist Therapeutics Earnings and Revenue History

Protagonist Therapeutics Debt to Assets

Protagonist Therapeutics Cash Flow

Protagonist Therapeutics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis